*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2025 | Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes The New England journal of medicine · human | PMID 41406444 |
| 2025 | Tirzepatide as Compared with Semaglutide for the Treatment of Obesity The New England journal of medicine · human | PMID 40353578 |
| 2025 | Tirzepatide for overweight and obesity management Expert opinion on pharmacotherapy · preclinical | PMID 39632534 |
| 2025 | Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation Cell metabolism · human | PMID 40203836 |
| 2025 | Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction JAMA · preclinical | PMID 40886075 |
| 2024 | Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial JAMA · human | PMID 38078870 |
| 2024 | Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics American heart journal · preclinical | PMID 37758044 |
| 2024 | Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity JAMA internal medicine · preclinical | PMID 38976257 |
| 2024 | Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis The New England journal of medicine · human | PMID 38856224 |
| 2024 | Tirzepatide: A Review in Type 2 Diabetes Drugs · preclinical | PMID 38388874 |
| 2024 | Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Diabetologia · preclinical | PMID 38613667 |
| 2024 | The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception Journal of the American Pharmacists Association : JAPhA · preclinical | PMID 37940101 |
| 2024 | Tirzepatide and exercise training in obesity Clinical hemorheology and microcirculation · human | PMID 38640145 |
| 2023 | Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes Diabetes care · human | PMID 36857477 |
| 2023 | Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial JAMA · human | PMID 37786396 |
| 2023 | New Drug: Tirzepatide (Mounjaro(™)) The Senior care pharmacist · preclinical | PMID 36751934 |
| 2023 | Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management Journal of obesity & metabolic syndrome · preclinical | PMID 36750526 |
| 2022 | Tirzepatide: A Systematic Update International journal of molecular sciences · preclinical | PMID 36498958 |
| 2022 | Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial JAMA · human | PMID 35133415 |
| 2022 | Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis Nature medicine · preclinical | PMID 35210595 |
| 2022 | Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial The lancet. Diabetes & endocrinology · human | PMID 35914543 |
| 2021 | Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes The New England journal of medicine · human | PMID 34170647 |
| 2021 | Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Lancet (London, England) · human | PMID 34186022 |
| 2021 | Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial Lancet (London, England) · human | PMID 34672967 |
| 2020 | Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist JCI insight · preclinical | PMID 32730231 |
Tirzepatide (Tirzepatide (dual GIP/GLP-1 receptor agonist)). Dual agonist of GIP and GLP-1 receptors. Combines incretin pathways to improve insulin secretion and sensitivity, reduce appetite, and slow gastric emptying.
Commonly discussed uses: type 2 diabetes, chronic weight management. There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Dual agonist of GIP and GLP-1 receptors. Combines incretin pathways to improve insulin secretion and sensitivity, reduce appetite, and slow gastric emptying.
Reported considerations: nausea, diarrhoea, decreased appetite, rare: pancreatitis, gallbladder events, thyroid C-cell warning (rodent). There is both human and animal/preclinical research, though the depth and quality vary by indication. FDA/TGA/MHRA-APPROVED prescription drug. Grey-market 'research' tirzepatide is not the approved product. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 2.5mg/week (start), typical 5-10mg/week, high 15mg/week. Administration: subcutaneous. Half-life: ~5 days.
Australian status: Prescription-only (S4); ARTG-registered (Mounjaro). FDA/TGA/MHRA-APPROVED prescription drug. Grey-market 'research' tirzepatide is not the approved product. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: approved product pre-filled; compounded vials vary; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): prescriber-directed; not for self-stacking. Stacking increases interaction/safety uncertainty.